SlideShare a Scribd company logo
1 of 8
Download to read offline
the way we do itHeader-solution
Pharmaceutical Mergers and
Acquisitions in the U.S.
Analyzing the correlation between new drug approvals and M&A activity
2015
2 Pharmaceutical Mergers and Acquisitions in the U.S.
Key Findings
• Since 2014, the pharmaceutical industry
has seen a wave of larger M&A deals
driven by opportunities for revenue
growth, cost synergies, tax inversion, and
cash utilization
• While megadeals (deals greater than
$5bn) have inflated deal value, the deal
volume has been driven by smaller,
product-focused acquisitions
• Over the past decade, there has been
an increase in the valuation multiples
that pharmaceutical and biotechnology
companies have received
• New drug approval is an acquisition trigger;
approximately one third of small and mid-
sized pharmaceutical firms (companies
with less than $15bn in 2014 revenues) that
received approval from Food and Drug
Administration for a new product were
acquired; 90% of these product-driven
acquisitions happened within six months of
FDA approval
U.S. Pharma M&A
Activity Overview
Since 2010, approximately 200 pharmaceutical
and biotech deals have taken place per year in
the United States. In 2014, only 182 major
deals took place, lower than average (~190).
However, 2014 surpassed the combined value
of deals from 2011-2013 ($178bn) and saw
over $200bn in mergers and acquisitions, a
300% increase from the previous year.
2014 saw several of the largest deals in the
pharmaceutical industry to date, including the
$66bn purchase of Allergan by Actavis, Merck
unloading its consumer health unit to Bayer,
GSK and Novartis’ multibillion-dollar asset
swap, as well as Novartis’s animal health unit
sale to Eli Lilly.
2015 will likely be an even bigger year for
pharmaceutical deals. Companies are
constantly looking for opportunities to bolster
portfolios and increase shareholder value. Over
$150bn of merger and acquisition activity was
recorded by U.S. pharmaceutical industry
through August 2015, and this figure will likely
exceed $220bn by year-end.
There has also been a shift in deal value from
2013 to 2014. The average deal size in 2013
was approximately $40m, while the average
deal size in 2014 was over $1bn, underscoring
industry’s appetite for larger deals.
Figure 1: Size and number of deals by U.S. pharmaceutical and biotech companies since 2007
Source: FiercePharma, EvaluatePharma, Capgemini Analysis
$70
$109
$152
$109
$56
$43
$79
$212
$151
$73
170
188
171
194
197
192 193
182
100
125
150
175
200
225
0
50
100
150
200
250
2007 2008 2009 2010 2011 2012 2013 2014 2015
DealCount
DealValue($Bn)
Year
M&A Activity in Pharma and Biotech
Deal Value Projected Deal Count
2014 surpassed the
combined total for
deals from 2011-
2013 and saw
over $200bn in
pharma mergers and
acquisitions, a 300%
increase from the
previous year’’
3
Factors Driving
Acquisitions
The size of recent deals disguises the true
characteristics of pharmaceutical mergers
and acquisitions activity. Although major
acquisitions outweigh other deals by value,
over 90% of deals were relatively small in size
(less than $5bn) (see Figure 2). The difference
in deal value appears to be driven by different
motives. For megadeals, motivations from
large pharmaceutical companies, such as
top-line increases, cost synergies, tax
inversion or cash utilization, frequently came
into play. In contrast, the smaller deals tended
to be much more focused, with target
companies offering different sources of value
to the acquirer, such as research or portfolio
expertise, a breakthrough pipeline drug, or a
recent drug approval.
A closer look at recent drug approvals reveals
an interesting correlation with acquisitions of
small and mid-sized companies. Of the 105
drugs approved in the U.S. since January
2014, 58% were filed by companies with less
that $15bn in 2014 revenues (see Figure 3). Of
the 16 large companies (with 2014 revenues
greater than $15bn) that had one or more
new drug approvals in the past 20 months,
none were acquired within the same period.
In comparison, 26% of small to mid-sized
pharmaceutical companies with new drug
approvals were acquired within that time
period. The fact that the small and mid-sized
companies acquired since January 2014
typically had no more than a few approved
products supports the observation that the
motivations behind large deals are very
different than those behind smaller deals.
So what makes a particular small to mid-
sized pharmaceutical company attractive
to potential acquirers? Following factors
have been resonant themes across
recent acquisitions:
• New drug approval with promising
estimated peak sales
• Special FDA status for existing or pipeline
products (breakthrough therapy, fast track
review, orphan drug designation, priority
review)
• Proven R&D leadership in a specific
technology or therapeutic area
• Relatively small market capitalization
Figure 2: U.S. pharmaceutical and biotech deals by value and count since January 2014
Source: FiercePharma, CrunchBase, EvaluatePharma, Capgemini Analysis
89%
11%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Megadeals
($5 bn+)
Other Deals
(< $5 bn)
Deal Value
6%
94%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Megadeals
($5 bn+)
Other Deals
(< $5 bn)
# of Deals
26% of small to mid-
sized pharmaceutical
companies with new
drug approvals were
acquired in past 20
months’’
4 Pharmaceutical Mergers and Acquisitions in the U.S.
Figure 3: New drug approvals by FDA since January 2014 across companies
Source: FDA, Capgemini Analysis
New Drug Approval as
an Acquisition Trigger
Any acquisition is a result of various
interrelated factors. Failure of bigger
pharmaceutical companies to consistently
develop new drugs and pressure from
shareholders to deliver returns have forced
large pharmaceutical companies to look
outside for innovative drugs. This has resulted
in new drug approvals emerging as a major
trigger for acquisitions. Capgemini Consulting
collected the data for all the new drug
approvals from January 2014 through August
2015 to analyze the correlation between new
drug approvals and acquisitions. Companies
that received the approvals were segmented
into large, mid-size and small based upon
their 2014 revenues (large >=$15bn, $15bn <
mid <$5bn, small <=$5bn).
Since there were no acquisitions in the large
segment over last 20 months, the analysis
focuses on the small to mid-sized
pharmaceutical companies. Figure 4 shows
the correlation between small to mid-sized
pharmaceutical companies, that were
acquired in last 20 months with the new
drug approvals.
As seen in Figure 4, all companies, with the
exception of Chelsea Therapeutics, were
acquired within six-months of obtaining FDA
approval. Excluding Forest Laboratories, in
cases where a company was acquired prior to
drug approval [denoted by (-)], the period
between approval and acquisition was less
than six months, meaning that the drug was
under FDA review when the deal was finalized.
Not surprisingly, in the two cases (Zerbaxa and
Natpara) where the drug was expected to be a
blockbuster, the company was acquired within
days of receiving FDA approval.
Of the small and mid-sized companies with
new drug approvals that have not yet been
acquired, four have already been predicted by
Wall Street as the next probable targets.
Furthermore, some of the companies with
new drug approval possess certain
characteristics that make them unattractive
acquisition targets. Some companies, such
as Mannkind and Pharming Group, have
strategically established relationships with Big
Pharmaceutical companies that deter other
companies from attempting an acquisition.
Others, such as Knight Therapeutics and The
Medicines Company, have opted to increase
their market capitalization through
Most small to mid-
sized pharmaceutical
companies that
received new drug
approval from FDA
were acquired within
six months.’’
42%
13%
45%
Recent Drug Approvals (since January 2014)
Large Pharma (2014
Revenue > = $15bn)
Mid-Sized Pharma
Small Pharma companies
(2014 Revenue < = $5bn)
5
Figure 4: Relationship between new drug approval and acquisition for small- and mid-sized pharmaceuticals since
January 2014
acquisitions of their own. The remaining few
are too small to be attractive acquisitions (i.e.
single product companies with less than
$100mm projected peak sales).
Hence, any small to mid-sized pharmaceutical
company nearing a product approval from
FDA should consider potential acquisition as a
risk and take necessary steps to prepare for it.   
Source: Capgemini Analysis
2014
Jan Feb March April May June July Aug Sept Oct Nov Dec Jan Feb March April May June July Aug
2015
FDA Approval Date
Acquisition Date
Product (Acquired / Buyer)
$100-
200M
$200-
300M
$300-
400M
$400-
500M
>$1B$500M-
1B
Estimated Peak Product Sales
Time Elapsed Between New Drug Approvals
and Acquisitions
Legend
Northera
(Chelsea Thpts / Lundbeck)
Sivextro
(Cubist / Merck)
Zerbaxa
(Cubist / Merck)
Cholmbam
(Asklepion / Retrophin)
Esbriet
(InterMune / Roche)
Natpara
(NPS / Shire)
Addyi
(Sprout / Valeant)
Kybella
(Kythera Biopharma / Allergan)
Dalvance
(Durata Therpeutics / Actavis)
(-)3 mths
Soolantra
(Galderma / Nestle)
(-) 5 mths
(+) 6 mths
(+) 15 mths
(-) 3 mths
(+) 5 mths
(-) 2 mths
Namzaric
(Forest Laboratories / Actavis)
Imbruvica
(Pharmacyclics / Abbvie)
Xifaxan
(Salix Pharmaceutical / Valeant)
(-)2 mths
(+) 6 mths
(-)10 mths
6 Pharmaceutical Mergers and Acquisitions in the U.S.
Figure 5: Median EBITDA multiple paid to acquire pharmaceutical and biotechnology companies, 2007-2015
Source: Bloomberg, Capgemini Analysis
Valuation
One of the first steps that a pharmaceutical
company can take to be better prepared for a
potential acquisition is to have an estimate of
their own valuation. Over the past decade,
there has been an increase in acquisition
prices for pharmaceutical and biotechnology
companies. Acquisition prices in 2015 are
highest relative to EBITA and revenue in last
20 years. Also market is eager to invest and
pay rich multiples for potential high payout
that exists.
The valuation process for pharmaceutical and
biotechnology companies presents a
challenge, as products in the early stages of
development have no product revenue on
which to base a valuation. Nevertheless,
valuations are continuously being performed
and adjusted, using available data, while also
being influenced by investor speculations
regarding the value of a particular company
or pipeline product. Due to lack of
transparency in the process, it is not rare to
find instances where pharmaceutical and
biotechnology companies sell promising
products, based on very low valuations, and
these products later, and sometimes very
quickly, become significantly more valuable.
Examples of these errors in valuation span
across disease areas, and include such
products as Zytiga, a drug that treats
prostrate cancer in men which became a
$2bn drug (sold by BTG for ~$6mm a year
royalty), and Cubicin, used to treat bacterial
infection with annual sales of over $1bn (sold
by Eli Lilly for less than $50mm).
These challenges are more pronounced in
valuing orphan drugs. Orphan drugs have
small patient population coupled with the
attractive pricing structure of the market.
This magnifies the errors in valuation process
leading to variance that can completely skew
the numbers.
Given the high degree of uncertainty and
reliance on assumptions that exist in
valuations for pharmaceutical and
biotechnology companies, as well as the
increase in deal value, it is becoming
increasingly important for these companies to
select their partners carefully, so as to ensure
that these valuations incorporate all relevant
information.
0
5
10
15
20
25
30
2007 2008 2009 2010 2011 2012 2013 2014 2015
MedianEBITDAMultiple(x)
Pharmaceutical and Biotechnology Median
Acquisition Multiples
Pharmaceutical
multiples have
steadily increased
over past 20 years’’
It is important for
pharmaceutical
companies to
select their valuation
partners carefully’’
7
Implications
What are the implications for small to
mid-sized companies that are in the process
of developing and launching new drugs?
There are a few steps that the potential target
company can take to be better prepared for
such a scenario. These are:
•	 Remain informed of current market
focus and incentives for mergers and
acquisitions, specifically related to types of
products and portfolios
•	 Estimate their global valuation, including
value of both the lead product as well as
the pipeline
•	 While performing valuations, select
partners carefully so as to ensure that
all relevant information is appropriately
captured
•	 Get a better understanding of the
corporate law of their home country as well
as that of the U.S.
•	 Review their ownership structure and have
a plan ready to respond to any unsolicited
third-party interest
•	 Develop relationships with key investors
to ensure their ongoing commitment and
understand relevant motivations
•	 In the case that the company is open
to a merger or acquisition, they should
proactively identify potential companies
that might be a good strategic fit
•	 Identify acquisition targets of their own
to increase market capitalization and
deter acquisition
References
1. “2014 FDA Approved Drugs” CenterWatch. Accessed September 2, 2015 2. Acquisition details from BioSpace. Accessed
September 2, 2015 3. Company profiles from CrunchBase. Accessed September 2, 2015 4. Gardner, J. & Urquhart, L. (2015) “Pharma
and Biotech Half-Year Review”. Evaluate Ltd., Accessed September 2, 2015 5. Helfand, C. & Palmer, E. (2015) “Pharma’s top 10 M&A
deals of 2014”. FiercePharma. Accessed September 2, 2015 6. Helfand, C. & Palmer, E. (2014) “Pharma’s top 10 M&A deals of 2014’s
first half”. FiercePharma. Accessed September 2, 2015 7. Lachapelle, Tara (2015) “Drug Takeover Valuations Soar as Par Pharma
Gains 300%”. Bloomberg data. Accessed September 20, 2015 8. Jarvis, L.M. (2015) “The Year in New Drugs”. Chemical & Engineering
News, 93(5): 11-16 9. “Orphan Drug Report” EvaluatePharma, 2014
the way we do itHeader-solution
The information contained in this document is proprietary. ©2015 Capgemini.
All rights reserved. Rightshore®
is a trademark belonging to Capgemini.
About the Authors
Sheetal Chawla is Principal Consultant at Capgemini Consulting and leads Digital and Commercial Strategy in the
North America Life Sciences practice (New York). She has more than 12 years of experience in business strategy,
market analytics, marketing and business development / valuation. In her role, she advises clients on commercial,
launch and patient strategies, digital transformation, and portfolio / profit optimization, among other topics. She can
be reached at sheetal.chawla@capgemini.com
Rohit Bansal is Managing Consultant at Capgemini Consulting within North America Life Sciences practice (New
York). He has over 10 years of experience of working with pharmaceutical clients in the area of commercial strategy,
process optimization, business analytics and planning. His areas of expertise are market potential assessments and
transformative business strategy development. He can be reached at rohit.bansal@capgemini.com
Contributors
Alexandra Alpaugh, Capgemini Consulting – New York
Betsy Dolan, Capgemini Consulting – New York
Rohit Mahajan, Capgemini Consulting – New York
The information contained in this document is proprietary. ©2015 Capgemini.
All rights reserved. Rightshore®
is a trademark belonging to Capgemini.
About Capgemini Consulting
Capgemini Consulting is the global strategy and transformation consulting organization of the Capgemini Group,
specializing in advising and supporting enterprises in significant transformation, from innovative strategy to execution
and with an unstinting focus on results. With the new digital economy creating significant disruptions and
opportunities, our global team of over 3,600 talented individuals work with leading companies and governments to
master Digital Transformation, drawing on our understanding of the digital economy and our leadership in business
transformation and organizational change.
For more information:
www.capgemini-consulting.com
About Capgemini
With 180,000 people in over 40 countries, Capgemini is one of the world’s foremost providers of consulting,
technology and outsourcing services. The Group reported 2014 global revenues of EUR 10.573 billion (about $14
billion USD at 2014 average rate). Together with its clients, Capgemini creates and delivers business, technology
and digital solutions that fit their needs, enabling them to achieve innovation and competitiveness. A deeply
multicultural organization, Capgemini has developed its own way of working, the Collaborative Business
ExperienceTM, and draws on Rightshore®
, its worldwide delivery model.
Learn more about us at
www.capgemini.com
Rightshore®
is a trademark belonging to Capgemini

More Related Content

What's hot

Digital Marketing in Pharma (India)
Digital Marketing in Pharma (India)Digital Marketing in Pharma (India)
Digital Marketing in Pharma (India)Gurpinder Singh
 
Pharmaceutical Marketing Management.ppt
Pharmaceutical Marketing Management.pptPharmaceutical Marketing Management.ppt
Pharmaceutical Marketing Management.pptHarshadaa bafna
 
Direct to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertisingDirect to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertisingNazmul Hasan Mahmud
 
Professional sales representative PSR
Professional sales representative PSR Professional sales representative PSR
Professional sales representative PSR Sharfuddeen Khan
 
Drug Price Control Order
Drug Price Control OrderDrug Price Control Order
Drug Price Control OrderIshitaDhingra1
 
Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup Animesh Gupta
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketingUzair Ahmed
 
Poverty and health . Social and preventive pharmacy
Poverty and health . Social and preventive pharmacyPoverty and health . Social and preventive pharmacy
Poverty and health . Social and preventive pharmacySusmitaGhosh94
 
Brand Plan for Vitamin D
Brand Plan  for  Vitamin DBrand Plan  for  Vitamin D
Brand Plan for Vitamin DBHARATH G
 
Digital Marketing for Pharma
Digital Marketing for PharmaDigital Marketing for Pharma
Digital Marketing for PharmaSimon Revell
 
Marketing Plan of Telmisartan_ by Shahid Khan.pptx
Marketing Plan of Telmisartan_ by Shahid Khan.pptxMarketing Plan of Telmisartan_ by Shahid Khan.pptx
Marketing Plan of Telmisartan_ by Shahid Khan.pptxShahid Khan
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XSatyajit Hui
 
Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...
Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...
Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...Association for Project Management
 

What's hot (20)

EUROPEAN UNION.pptx
EUROPEAN UNION.pptxEUROPEAN UNION.pptx
EUROPEAN UNION.pptx
 
Digital Marketing in Pharma (India)
Digital Marketing in Pharma (India)Digital Marketing in Pharma (India)
Digital Marketing in Pharma (India)
 
Pharmaceutical Marketing Management.ppt
Pharmaceutical Marketing Management.pptPharmaceutical Marketing Management.ppt
Pharmaceutical Marketing Management.ppt
 
Direct to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertisingDirect to consumer pharmaceutical advertising
Direct to consumer pharmaceutical advertising
 
Esomeprazole plan
Esomeprazole planEsomeprazole plan
Esomeprazole plan
 
Drug Purchasing & Pricing : industry perspective
Drug Purchasing & Pricing : industry perspectiveDrug Purchasing & Pricing : industry perspective
Drug Purchasing & Pricing : industry perspective
 
Professional sales representative PSR
Professional sales representative PSR Professional sales representative PSR
Professional sales representative PSR
 
Drug Price Control Order
Drug Price Control OrderDrug Price Control Order
Drug Price Control Order
 
Brand plan on cough syrup
Brand plan on cough syrup Brand plan on cough syrup
Brand plan on cough syrup
 
Pharma marketing
Pharma marketingPharma marketing
Pharma marketing
 
Poverty and health . Social and preventive pharmacy
Poverty and health . Social and preventive pharmacyPoverty and health . Social and preventive pharmacy
Poverty and health . Social and preventive pharmacy
 
Brand Plan for Vitamin D
Brand Plan  for  Vitamin DBrand Plan  for  Vitamin D
Brand Plan for Vitamin D
 
Pharmaceutical Marketing
Pharmaceutical MarketingPharmaceutical Marketing
Pharmaceutical Marketing
 
Detailing
DetailingDetailing
Detailing
 
International marketing
International marketingInternational marketing
International marketing
 
Digital Marketing for Pharma
Digital Marketing for PharmaDigital Marketing for Pharma
Digital Marketing for Pharma
 
Marketing Plan of Telmisartan_ by Shahid Khan.pptx
Marketing Plan of Telmisartan_ by Shahid Khan.pptxMarketing Plan of Telmisartan_ by Shahid Khan.pptx
Marketing Plan of Telmisartan_ by Shahid Khan.pptx
 
Brand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-XBrand Plan for the launch of Brand-X
Brand Plan for the launch of Brand-X
 
Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...
Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...
Portfolio Management in the pharmaceutical industry by Dr John Bennett, 10th ...
 
Marketing Plan
Marketing PlanMarketing Plan
Marketing Plan
 

Viewers also liked

Apps to Explore Outer Space
Apps to Explore Outer SpaceApps to Explore Outer Space
Apps to Explore Outer SpaceMonica Burns
 
Chapter 13 Psychiatric Medications
Chapter 13   Psychiatric MedicationsChapter 13   Psychiatric Medications
Chapter 13 Psychiatric MedicationsJustin Gatewood
 
The quest for value in health care: A place for consumers
The quest for value in health care: A place for consumersThe quest for value in health care: A place for consumers
The quest for value in health care: A place for consumersDeloitte United States
 
How Data Saves Time
How Data Saves TimeHow Data Saves Time
How Data Saves TimeNetApp
 
Making Data Work
Making Data WorkMaking Data Work
Making Data WorkNetApp
 
Medicare 101 - February 2017 Update
Medicare 101 - February 2017 UpdateMedicare 101 - February 2017 Update
Medicare 101 - February 2017 UpdateMary Hagan
 
Data-driven decisions for healthcare - Unleash Enterprise Innovation3
Data-driven decisions for healthcare - Unleash Enterprise Innovation3Data-driven decisions for healthcare - Unleash Enterprise Innovation3
Data-driven decisions for healthcare - Unleash Enterprise Innovation3Capgemini
 
Transformational themes that will shake the world of healthcare improvement
 Transformational themes that will shake the world of healthcare improvement Transformational themes that will shake the world of healthcare improvement
Transformational themes that will shake the world of healthcare improvementNHS Improving Quality
 
Patient Engagement
Patient EngagementPatient Engagement
Patient Engagementathenahealth
 

Viewers also liked (14)

Healthcare
HealthcareHealthcare
Healthcare
 
Psychopharmacology
PsychopharmacologyPsychopharmacology
Psychopharmacology
 
Powerpoint
PowerpointPowerpoint
Powerpoint
 
Apps to Explore Outer Space
Apps to Explore Outer SpaceApps to Explore Outer Space
Apps to Explore Outer Space
 
Chapter 13 Psychiatric Medications
Chapter 13   Psychiatric MedicationsChapter 13   Psychiatric Medications
Chapter 13 Psychiatric Medications
 
Antidepressants Tca Ssri
Antidepressants   Tca SsriAntidepressants   Tca Ssri
Antidepressants Tca Ssri
 
The quest for value in health care: A place for consumers
The quest for value in health care: A place for consumersThe quest for value in health care: A place for consumers
The quest for value in health care: A place for consumers
 
How Data Saves Time
How Data Saves TimeHow Data Saves Time
How Data Saves Time
 
Making Data Work
Making Data WorkMaking Data Work
Making Data Work
 
Medicare 101 - February 2017 Update
Medicare 101 - February 2017 UpdateMedicare 101 - February 2017 Update
Medicare 101 - February 2017 Update
 
Data-driven decisions for healthcare - Unleash Enterprise Innovation3
Data-driven decisions for healthcare - Unleash Enterprise Innovation3Data-driven decisions for healthcare - Unleash Enterprise Innovation3
Data-driven decisions for healthcare - Unleash Enterprise Innovation3
 
Transformational themes that will shake the world of healthcare improvement
 Transformational themes that will shake the world of healthcare improvement Transformational themes that will shake the world of healthcare improvement
Transformational themes that will shake the world of healthcare improvement
 
Patient Engagement
Patient EngagementPatient Engagement
Patient Engagement
 
FMCC 2016 MACRA Plenary by Amy Mullins
FMCC 2016 MACRA Plenary by Amy MullinsFMCC 2016 MACRA Plenary by Amy Mullins
FMCC 2016 MACRA Plenary by Amy Mullins
 

Similar to Pharmaceutical Mergers Acquisitions in the U.S

Pharmaceutical Mergs Acquisitions in the US
Pharmaceutical Mergs Acquisitions in the USPharmaceutical Mergs Acquisitions in the US
Pharmaceutical Mergs Acquisitions in the USCapgemini
 
Merck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio AnalysisMerck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio AnalysisJason Sandoy
 
2015 Unpartnered Products update
2015 Unpartnered Products update2015 Unpartnered Products update
2015 Unpartnered Products updateYujia Sun
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug ReportBill Smith
 
The future of the pharma industry 11.07
The future of the pharma industry 11.07The future of the pharma industry 11.07
The future of the pharma industry 11.07Maria Zaritskaya
 
Biotechnology Publication
Biotechnology PublicationBiotechnology Publication
Biotechnology PublicationChad Houston
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9Yousaf Khan
 
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerAntitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerNexsen Pruet
 
Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015DiplomatIR
 
Sales Model Paradigm Shift
Sales Model Paradigm ShiftSales Model Paradigm Shift
Sales Model Paradigm Shiftjskahan
 
99580907 global-cro-report
99580907 global-cro-report99580907 global-cro-report
99580907 global-cro-reportpatyi_2000
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]WriteKraft Dissertations
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]WriteKraft Dissertations
 

Similar to Pharmaceutical Mergers Acquisitions in the U.S (20)

Pharmaceutical Mergs Acquisitions in the US
Pharmaceutical Mergs Acquisitions in the USPharmaceutical Mergs Acquisitions in the US
Pharmaceutical Mergs Acquisitions in the US
 
Merck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio AnalysisMerck Paper Securities and Protfolio Analysis
Merck Paper Securities and Protfolio Analysis
 
2015 Unpartnered Products update
2015 Unpartnered Products update2015 Unpartnered Products update
2015 Unpartnered Products update
 
Orphan Drug Report
Orphan Drug ReportOrphan Drug Report
Orphan Drug Report
 
5 Myths of Drug Delivery
5 Myths of Drug Delivery5 Myths of Drug Delivery
5 Myths of Drug Delivery
 
5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]
 
The future of the pharma industry 11.07
The future of the pharma industry 11.07The future of the pharma industry 11.07
The future of the pharma industry 11.07
 
Biotechnology Publication
Biotechnology PublicationBiotechnology Publication
Biotechnology Publication
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
 
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug ManufacturerAntitrust Aspects of Acquiring a Generic Drug Manufacturer
Antitrust Aspects of Acquiring a Generic Drug Manufacturer
 
Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015Dsp investor deck william blair june 2015
Dsp investor deck william blair june 2015
 
Sales Model Paradigm Shift
Sales Model Paradigm ShiftSales Model Paradigm Shift
Sales Model Paradigm Shift
 
biotech
biotechbiotech
biotech
 
99580907 global-cro-report
99580907 global-cro-report99580907 global-cro-report
99580907 global-cro-report
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing[www.writekraft.com]
A review of marketing[www.writekraft.com]A review of marketing[www.writekraft.com]
A review of marketing[www.writekraft.com]
 
A review of marketing
A review of marketingA review of marketing
A review of marketing
 
A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]A review of marketing [www.writekraft.com]
A review of marketing [www.writekraft.com]
 

More from Capgemini

Top Healthcare Trends 2022
Top Healthcare Trends 2022Top Healthcare Trends 2022
Top Healthcare Trends 2022Capgemini
 
Top P&C Insurance Trends 2022
Top P&C Insurance Trends 2022Top P&C Insurance Trends 2022
Top P&C Insurance Trends 2022Capgemini
 
Commercial Banking Trends book 2022
Commercial Banking Trends book 2022Commercial Banking Trends book 2022
Commercial Banking Trends book 2022Capgemini
 
Top Trends in Payments 2022
Top Trends in Payments 2022Top Trends in Payments 2022
Top Trends in Payments 2022Capgemini
 
Top Trends in Wealth Management 2022
Top Trends in Wealth Management 2022Top Trends in Wealth Management 2022
Top Trends in Wealth Management 2022Capgemini
 
Retail Banking Trends book 2022
Retail Banking Trends book 2022Retail Banking Trends book 2022
Retail Banking Trends book 2022Capgemini
 
Top Life Insurance Trends 2022
Top Life Insurance Trends 2022Top Life Insurance Trends 2022
Top Life Insurance Trends 2022Capgemini
 
キャップジェミニ、あなたの『RISE WITH SAP』のパートナーです
キャップジェミニ、あなたの『RISE WITH SAP』のパートナーですキャップジェミニ、あなたの『RISE WITH SAP』のパートナーです
キャップジェミニ、あなたの『RISE WITH SAP』のパートナーですCapgemini
 
Property & Casualty Insurance Top Trends 2021
Property & Casualty Insurance Top Trends 2021Property & Casualty Insurance Top Trends 2021
Property & Casualty Insurance Top Trends 2021Capgemini
 
Life Insurance Top Trends 2021
Life Insurance Top Trends 2021Life Insurance Top Trends 2021
Life Insurance Top Trends 2021Capgemini
 
Top Trends in Commercial Banking: 2021
Top Trends in Commercial Banking: 2021Top Trends in Commercial Banking: 2021
Top Trends in Commercial Banking: 2021Capgemini
 
Top Trends in Wealth Management: 2021
Top Trends in Wealth Management: 2021Top Trends in Wealth Management: 2021
Top Trends in Wealth Management: 2021Capgemini
 
Top Trends in Payments: 2021
Top Trends in Payments: 2021Top Trends in Payments: 2021
Top Trends in Payments: 2021Capgemini
 
Health Insurance Top Trends 2021
Health Insurance Top Trends 2021Health Insurance Top Trends 2021
Health Insurance Top Trends 2021Capgemini
 
Top Trends in Retail Banking: 2021
Top Trends in Retail Banking: 2021Top Trends in Retail Banking: 2021
Top Trends in Retail Banking: 2021Capgemini
 
Capgemini’s Connected Autonomous Planning
Capgemini’s Connected Autonomous PlanningCapgemini’s Connected Autonomous Planning
Capgemini’s Connected Autonomous PlanningCapgemini
 
Top Trends in Retail Banking: 2020
Top Trends in Retail Banking: 2020Top Trends in Retail Banking: 2020
Top Trends in Retail Banking: 2020Capgemini
 
Top Trends in Life Insurance: 2020
Top Trends in Life Insurance: 2020Top Trends in Life Insurance: 2020
Top Trends in Life Insurance: 2020Capgemini
 
Top Trends in Health Insurance: 2020
Top Trends in Health Insurance: 2020Top Trends in Health Insurance: 2020
Top Trends in Health Insurance: 2020Capgemini
 
Top Trends in Payments: 2020
Top Trends in Payments: 2020Top Trends in Payments: 2020
Top Trends in Payments: 2020Capgemini
 

More from Capgemini (20)

Top Healthcare Trends 2022
Top Healthcare Trends 2022Top Healthcare Trends 2022
Top Healthcare Trends 2022
 
Top P&C Insurance Trends 2022
Top P&C Insurance Trends 2022Top P&C Insurance Trends 2022
Top P&C Insurance Trends 2022
 
Commercial Banking Trends book 2022
Commercial Banking Trends book 2022Commercial Banking Trends book 2022
Commercial Banking Trends book 2022
 
Top Trends in Payments 2022
Top Trends in Payments 2022Top Trends in Payments 2022
Top Trends in Payments 2022
 
Top Trends in Wealth Management 2022
Top Trends in Wealth Management 2022Top Trends in Wealth Management 2022
Top Trends in Wealth Management 2022
 
Retail Banking Trends book 2022
Retail Banking Trends book 2022Retail Banking Trends book 2022
Retail Banking Trends book 2022
 
Top Life Insurance Trends 2022
Top Life Insurance Trends 2022Top Life Insurance Trends 2022
Top Life Insurance Trends 2022
 
キャップジェミニ、あなたの『RISE WITH SAP』のパートナーです
キャップジェミニ、あなたの『RISE WITH SAP』のパートナーですキャップジェミニ、あなたの『RISE WITH SAP』のパートナーです
キャップジェミニ、あなたの『RISE WITH SAP』のパートナーです
 
Property & Casualty Insurance Top Trends 2021
Property & Casualty Insurance Top Trends 2021Property & Casualty Insurance Top Trends 2021
Property & Casualty Insurance Top Trends 2021
 
Life Insurance Top Trends 2021
Life Insurance Top Trends 2021Life Insurance Top Trends 2021
Life Insurance Top Trends 2021
 
Top Trends in Commercial Banking: 2021
Top Trends in Commercial Banking: 2021Top Trends in Commercial Banking: 2021
Top Trends in Commercial Banking: 2021
 
Top Trends in Wealth Management: 2021
Top Trends in Wealth Management: 2021Top Trends in Wealth Management: 2021
Top Trends in Wealth Management: 2021
 
Top Trends in Payments: 2021
Top Trends in Payments: 2021Top Trends in Payments: 2021
Top Trends in Payments: 2021
 
Health Insurance Top Trends 2021
Health Insurance Top Trends 2021Health Insurance Top Trends 2021
Health Insurance Top Trends 2021
 
Top Trends in Retail Banking: 2021
Top Trends in Retail Banking: 2021Top Trends in Retail Banking: 2021
Top Trends in Retail Banking: 2021
 
Capgemini’s Connected Autonomous Planning
Capgemini’s Connected Autonomous PlanningCapgemini’s Connected Autonomous Planning
Capgemini’s Connected Autonomous Planning
 
Top Trends in Retail Banking: 2020
Top Trends in Retail Banking: 2020Top Trends in Retail Banking: 2020
Top Trends in Retail Banking: 2020
 
Top Trends in Life Insurance: 2020
Top Trends in Life Insurance: 2020Top Trends in Life Insurance: 2020
Top Trends in Life Insurance: 2020
 
Top Trends in Health Insurance: 2020
Top Trends in Health Insurance: 2020Top Trends in Health Insurance: 2020
Top Trends in Health Insurance: 2020
 
Top Trends in Payments: 2020
Top Trends in Payments: 2020Top Trends in Payments: 2020
Top Trends in Payments: 2020
 

Recently uploaded

The Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of ArizonaThe Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of Arizonajackjohn60
 
Adrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfb
Adrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfbAdrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfb
Adrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfbKritikaMishra43
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.pdamico1
 
End of Response issues - Code and Rapid Response Workshop
End of Response issues - Code and Rapid Response WorkshopEnd of Response issues - Code and Rapid Response Workshop
End of Response issues - Code and Rapid Response WorkshopBrian Locke
 
mHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextmHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextLevi Shapiro
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationStartupSprouts.in
 
Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Brian Locke
 
Catheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptxCatheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptxAnushriSrivastav
 
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.pptSession-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.pptMedidas Medical Center INC
 
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, IndiaDr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, IndiaGaurav Gangwani
 
An overview of Muir Wood Adolescent and Family Services teen treatment progra...
An overview of Muir Wood Adolescent and Family Services teen treatment progra...An overview of Muir Wood Adolescent and Family Services teen treatment progra...
An overview of Muir Wood Adolescent and Family Services teen treatment progra...pdamico1
 
Breaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsBreaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsOppositional Defiant Disorder
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfد حاتم البيطار
 
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptxINTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptxAnushriSrivastav
 
The Power of Technology and Collaboration in Research - Rheumatology Research...
The Power of Technology and Collaboration in Research - Rheumatology Research...The Power of Technology and Collaboration in Research - Rheumatology Research...
The Power of Technology and Collaboration in Research - Rheumatology Research...Paul Sufka
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxBlake100757
 
Leadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response WorkshopLeadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response WorkshopBrian Locke
 
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxSession-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxMedidas Medical Center INC
 
Giudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfGiudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfDr. Afreen Nasir
 
Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt
Session-1-MBFHI-A-part-of-the-Global-Strategy.pptSession-1-MBFHI-A-part-of-the-Global-Strategy.ppt
Session-1-MBFHI-A-part-of-the-Global-Strategy.pptMedidas Medical Center INC
 

Recently uploaded (20)

The Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of ArizonaThe Best Foot and Ankle Center of Arizona
The Best Foot and Ankle Center of Arizona
 
Adrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfb
Adrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfbAdrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfb
Adrenal Function Tests-3.pptxwhfbdqbfwwfjgwngnegenhndngssfb
 
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.An overview of Muir Wood Adolescent and Family Services teen treatment programs.
An overview of Muir Wood Adolescent and Family Services teen treatment programs.
 
End of Response issues - Code and Rapid Response Workshop
End of Response issues - Code and Rapid Response WorkshopEnd of Response issues - Code and Rapid Response Workshop
End of Response issues - Code and Rapid Response Workshop
 
mHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes NextmHealth Israel_Healthcare Finance and M&A- What Comes Next
mHealth Israel_Healthcare Finance and M&A- What Comes Next
 
Mental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck PresentationMental Health Startup Pitch Deck Presentation
Mental Health Startup Pitch Deck Presentation
 
Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.Etiology for RRT and Code Blue Workshop.
Etiology for RRT and Code Blue Workshop.
 
Catheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptxCatheterization Procedure by Anushri Srivastav.pptx
Catheterization Procedure by Anushri Srivastav.pptx
 
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.pptSession-3-Promoting-Breastfeeding-During-Pregnancy.ppt
Session-3-Promoting-Breastfeeding-During-Pregnancy.ppt
 
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, IndiaDr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
Dr. Gaurav Gangwani: Leading Interventional Radiologist in Mumbai, India
 
An overview of Muir Wood Adolescent and Family Services teen treatment progra...
An overview of Muir Wood Adolescent and Family Services teen treatment progra...An overview of Muir Wood Adolescent and Family Services teen treatment progra...
An overview of Muir Wood Adolescent and Family Services teen treatment progra...
 
Breaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder TreatmentsBreaking Down Oppositional Defiant Disorder Treatments
Breaking Down Oppositional Defiant Disorder Treatments
 
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdfتقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
تقرير منظمة الصحة العالمية الخاص بالغذاء د حاتم البيطار.pdf
 
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptxINTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
INTERNATIONAL HEALTH AGENCIES BY ANUSHRI SRIVASTAV.pptx
 
The Power of Technology and Collaboration in Research - Rheumatology Research...
The Power of Technology and Collaboration in Research - Rheumatology Research...The Power of Technology and Collaboration in Research - Rheumatology Research...
The Power of Technology and Collaboration in Research - Rheumatology Research...
 
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptxPhRMA Vaccines Deck_05-15_2024_FINAL.pptx
PhRMA Vaccines Deck_05-15_2024_FINAL.pptx
 
Leadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response WorkshopLeadership Style - Code and Rapid Response Workshop
Leadership Style - Code and Rapid Response Workshop
 
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptxSession-17-KANGAROO-MOTHER-CARE_final-blue.pptx
Session-17-KANGAROO-MOTHER-CARE_final-blue.pptx
 
Giudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdfGiudeline: Adverse event CTCAE version 5.pdf
Giudeline: Adverse event CTCAE version 5.pdf
 
Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt
Session-1-MBFHI-A-part-of-the-Global-Strategy.pptSession-1-MBFHI-A-part-of-the-Global-Strategy.ppt
Session-1-MBFHI-A-part-of-the-Global-Strategy.ppt
 

Pharmaceutical Mergers Acquisitions in the U.S

  • 1. the way we do itHeader-solution Pharmaceutical Mergers and Acquisitions in the U.S. Analyzing the correlation between new drug approvals and M&A activity 2015
  • 2. 2 Pharmaceutical Mergers and Acquisitions in the U.S. Key Findings • Since 2014, the pharmaceutical industry has seen a wave of larger M&A deals driven by opportunities for revenue growth, cost synergies, tax inversion, and cash utilization • While megadeals (deals greater than $5bn) have inflated deal value, the deal volume has been driven by smaller, product-focused acquisitions • Over the past decade, there has been an increase in the valuation multiples that pharmaceutical and biotechnology companies have received • New drug approval is an acquisition trigger; approximately one third of small and mid- sized pharmaceutical firms (companies with less than $15bn in 2014 revenues) that received approval from Food and Drug Administration for a new product were acquired; 90% of these product-driven acquisitions happened within six months of FDA approval U.S. Pharma M&A Activity Overview Since 2010, approximately 200 pharmaceutical and biotech deals have taken place per year in the United States. In 2014, only 182 major deals took place, lower than average (~190). However, 2014 surpassed the combined value of deals from 2011-2013 ($178bn) and saw over $200bn in mergers and acquisitions, a 300% increase from the previous year. 2014 saw several of the largest deals in the pharmaceutical industry to date, including the $66bn purchase of Allergan by Actavis, Merck unloading its consumer health unit to Bayer, GSK and Novartis’ multibillion-dollar asset swap, as well as Novartis’s animal health unit sale to Eli Lilly. 2015 will likely be an even bigger year for pharmaceutical deals. Companies are constantly looking for opportunities to bolster portfolios and increase shareholder value. Over $150bn of merger and acquisition activity was recorded by U.S. pharmaceutical industry through August 2015, and this figure will likely exceed $220bn by year-end. There has also been a shift in deal value from 2013 to 2014. The average deal size in 2013 was approximately $40m, while the average deal size in 2014 was over $1bn, underscoring industry’s appetite for larger deals. Figure 1: Size and number of deals by U.S. pharmaceutical and biotech companies since 2007 Source: FiercePharma, EvaluatePharma, Capgemini Analysis $70 $109 $152 $109 $56 $43 $79 $212 $151 $73 170 188 171 194 197 192 193 182 100 125 150 175 200 225 0 50 100 150 200 250 2007 2008 2009 2010 2011 2012 2013 2014 2015 DealCount DealValue($Bn) Year M&A Activity in Pharma and Biotech Deal Value Projected Deal Count 2014 surpassed the combined total for deals from 2011- 2013 and saw over $200bn in pharma mergers and acquisitions, a 300% increase from the previous year’’
  • 3. 3 Factors Driving Acquisitions The size of recent deals disguises the true characteristics of pharmaceutical mergers and acquisitions activity. Although major acquisitions outweigh other deals by value, over 90% of deals were relatively small in size (less than $5bn) (see Figure 2). The difference in deal value appears to be driven by different motives. For megadeals, motivations from large pharmaceutical companies, such as top-line increases, cost synergies, tax inversion or cash utilization, frequently came into play. In contrast, the smaller deals tended to be much more focused, with target companies offering different sources of value to the acquirer, such as research or portfolio expertise, a breakthrough pipeline drug, or a recent drug approval. A closer look at recent drug approvals reveals an interesting correlation with acquisitions of small and mid-sized companies. Of the 105 drugs approved in the U.S. since January 2014, 58% were filed by companies with less that $15bn in 2014 revenues (see Figure 3). Of the 16 large companies (with 2014 revenues greater than $15bn) that had one or more new drug approvals in the past 20 months, none were acquired within the same period. In comparison, 26% of small to mid-sized pharmaceutical companies with new drug approvals were acquired within that time period. The fact that the small and mid-sized companies acquired since January 2014 typically had no more than a few approved products supports the observation that the motivations behind large deals are very different than those behind smaller deals. So what makes a particular small to mid- sized pharmaceutical company attractive to potential acquirers? Following factors have been resonant themes across recent acquisitions: • New drug approval with promising estimated peak sales • Special FDA status for existing or pipeline products (breakthrough therapy, fast track review, orphan drug designation, priority review) • Proven R&D leadership in a specific technology or therapeutic area • Relatively small market capitalization Figure 2: U.S. pharmaceutical and biotech deals by value and count since January 2014 Source: FiercePharma, CrunchBase, EvaluatePharma, Capgemini Analysis 89% 11% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Megadeals ($5 bn+) Other Deals (< $5 bn) Deal Value 6% 94% 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% Megadeals ($5 bn+) Other Deals (< $5 bn) # of Deals 26% of small to mid- sized pharmaceutical companies with new drug approvals were acquired in past 20 months’’
  • 4. 4 Pharmaceutical Mergers and Acquisitions in the U.S. Figure 3: New drug approvals by FDA since January 2014 across companies Source: FDA, Capgemini Analysis New Drug Approval as an Acquisition Trigger Any acquisition is a result of various interrelated factors. Failure of bigger pharmaceutical companies to consistently develop new drugs and pressure from shareholders to deliver returns have forced large pharmaceutical companies to look outside for innovative drugs. This has resulted in new drug approvals emerging as a major trigger for acquisitions. Capgemini Consulting collected the data for all the new drug approvals from January 2014 through August 2015 to analyze the correlation between new drug approvals and acquisitions. Companies that received the approvals were segmented into large, mid-size and small based upon their 2014 revenues (large >=$15bn, $15bn < mid <$5bn, small <=$5bn). Since there were no acquisitions in the large segment over last 20 months, the analysis focuses on the small to mid-sized pharmaceutical companies. Figure 4 shows the correlation between small to mid-sized pharmaceutical companies, that were acquired in last 20 months with the new drug approvals. As seen in Figure 4, all companies, with the exception of Chelsea Therapeutics, were acquired within six-months of obtaining FDA approval. Excluding Forest Laboratories, in cases where a company was acquired prior to drug approval [denoted by (-)], the period between approval and acquisition was less than six months, meaning that the drug was under FDA review when the deal was finalized. Not surprisingly, in the two cases (Zerbaxa and Natpara) where the drug was expected to be a blockbuster, the company was acquired within days of receiving FDA approval. Of the small and mid-sized companies with new drug approvals that have not yet been acquired, four have already been predicted by Wall Street as the next probable targets. Furthermore, some of the companies with new drug approval possess certain characteristics that make them unattractive acquisition targets. Some companies, such as Mannkind and Pharming Group, have strategically established relationships with Big Pharmaceutical companies that deter other companies from attempting an acquisition. Others, such as Knight Therapeutics and The Medicines Company, have opted to increase their market capitalization through Most small to mid- sized pharmaceutical companies that received new drug approval from FDA were acquired within six months.’’ 42% 13% 45% Recent Drug Approvals (since January 2014) Large Pharma (2014 Revenue > = $15bn) Mid-Sized Pharma Small Pharma companies (2014 Revenue < = $5bn)
  • 5. 5 Figure 4: Relationship between new drug approval and acquisition for small- and mid-sized pharmaceuticals since January 2014 acquisitions of their own. The remaining few are too small to be attractive acquisitions (i.e. single product companies with less than $100mm projected peak sales). Hence, any small to mid-sized pharmaceutical company nearing a product approval from FDA should consider potential acquisition as a risk and take necessary steps to prepare for it.    Source: Capgemini Analysis 2014 Jan Feb March April May June July Aug Sept Oct Nov Dec Jan Feb March April May June July Aug 2015 FDA Approval Date Acquisition Date Product (Acquired / Buyer) $100- 200M $200- 300M $300- 400M $400- 500M >$1B$500M- 1B Estimated Peak Product Sales Time Elapsed Between New Drug Approvals and Acquisitions Legend Northera (Chelsea Thpts / Lundbeck) Sivextro (Cubist / Merck) Zerbaxa (Cubist / Merck) Cholmbam (Asklepion / Retrophin) Esbriet (InterMune / Roche) Natpara (NPS / Shire) Addyi (Sprout / Valeant) Kybella (Kythera Biopharma / Allergan) Dalvance (Durata Therpeutics / Actavis) (-)3 mths Soolantra (Galderma / Nestle) (-) 5 mths (+) 6 mths (+) 15 mths (-) 3 mths (+) 5 mths (-) 2 mths Namzaric (Forest Laboratories / Actavis) Imbruvica (Pharmacyclics / Abbvie) Xifaxan (Salix Pharmaceutical / Valeant) (-)2 mths (+) 6 mths (-)10 mths
  • 6. 6 Pharmaceutical Mergers and Acquisitions in the U.S. Figure 5: Median EBITDA multiple paid to acquire pharmaceutical and biotechnology companies, 2007-2015 Source: Bloomberg, Capgemini Analysis Valuation One of the first steps that a pharmaceutical company can take to be better prepared for a potential acquisition is to have an estimate of their own valuation. Over the past decade, there has been an increase in acquisition prices for pharmaceutical and biotechnology companies. Acquisition prices in 2015 are highest relative to EBITA and revenue in last 20 years. Also market is eager to invest and pay rich multiples for potential high payout that exists. The valuation process for pharmaceutical and biotechnology companies presents a challenge, as products in the early stages of development have no product revenue on which to base a valuation. Nevertheless, valuations are continuously being performed and adjusted, using available data, while also being influenced by investor speculations regarding the value of a particular company or pipeline product. Due to lack of transparency in the process, it is not rare to find instances where pharmaceutical and biotechnology companies sell promising products, based on very low valuations, and these products later, and sometimes very quickly, become significantly more valuable. Examples of these errors in valuation span across disease areas, and include such products as Zytiga, a drug that treats prostrate cancer in men which became a $2bn drug (sold by BTG for ~$6mm a year royalty), and Cubicin, used to treat bacterial infection with annual sales of over $1bn (sold by Eli Lilly for less than $50mm). These challenges are more pronounced in valuing orphan drugs. Orphan drugs have small patient population coupled with the attractive pricing structure of the market. This magnifies the errors in valuation process leading to variance that can completely skew the numbers. Given the high degree of uncertainty and reliance on assumptions that exist in valuations for pharmaceutical and biotechnology companies, as well as the increase in deal value, it is becoming increasingly important for these companies to select their partners carefully, so as to ensure that these valuations incorporate all relevant information. 0 5 10 15 20 25 30 2007 2008 2009 2010 2011 2012 2013 2014 2015 MedianEBITDAMultiple(x) Pharmaceutical and Biotechnology Median Acquisition Multiples Pharmaceutical multiples have steadily increased over past 20 years’’ It is important for pharmaceutical companies to select their valuation partners carefully’’
  • 7. 7 Implications What are the implications for small to mid-sized companies that are in the process of developing and launching new drugs? There are a few steps that the potential target company can take to be better prepared for such a scenario. These are: • Remain informed of current market focus and incentives for mergers and acquisitions, specifically related to types of products and portfolios • Estimate their global valuation, including value of both the lead product as well as the pipeline • While performing valuations, select partners carefully so as to ensure that all relevant information is appropriately captured • Get a better understanding of the corporate law of their home country as well as that of the U.S. • Review their ownership structure and have a plan ready to respond to any unsolicited third-party interest • Develop relationships with key investors to ensure their ongoing commitment and understand relevant motivations • In the case that the company is open to a merger or acquisition, they should proactively identify potential companies that might be a good strategic fit • Identify acquisition targets of their own to increase market capitalization and deter acquisition References 1. “2014 FDA Approved Drugs” CenterWatch. Accessed September 2, 2015 2. Acquisition details from BioSpace. Accessed September 2, 2015 3. Company profiles from CrunchBase. Accessed September 2, 2015 4. Gardner, J. & Urquhart, L. (2015) “Pharma and Biotech Half-Year Review”. Evaluate Ltd., Accessed September 2, 2015 5. Helfand, C. & Palmer, E. (2015) “Pharma’s top 10 M&A deals of 2014”. FiercePharma. Accessed September 2, 2015 6. Helfand, C. & Palmer, E. (2014) “Pharma’s top 10 M&A deals of 2014’s first half”. FiercePharma. Accessed September 2, 2015 7. Lachapelle, Tara (2015) “Drug Takeover Valuations Soar as Par Pharma Gains 300%”. Bloomberg data. Accessed September 20, 2015 8. Jarvis, L.M. (2015) “The Year in New Drugs”. Chemical & Engineering News, 93(5): 11-16 9. “Orphan Drug Report” EvaluatePharma, 2014
  • 8. the way we do itHeader-solution The information contained in this document is proprietary. ©2015 Capgemini. All rights reserved. Rightshore® is a trademark belonging to Capgemini. About the Authors Sheetal Chawla is Principal Consultant at Capgemini Consulting and leads Digital and Commercial Strategy in the North America Life Sciences practice (New York). She has more than 12 years of experience in business strategy, market analytics, marketing and business development / valuation. In her role, she advises clients on commercial, launch and patient strategies, digital transformation, and portfolio / profit optimization, among other topics. She can be reached at sheetal.chawla@capgemini.com Rohit Bansal is Managing Consultant at Capgemini Consulting within North America Life Sciences practice (New York). He has over 10 years of experience of working with pharmaceutical clients in the area of commercial strategy, process optimization, business analytics and planning. His areas of expertise are market potential assessments and transformative business strategy development. He can be reached at rohit.bansal@capgemini.com Contributors Alexandra Alpaugh, Capgemini Consulting – New York Betsy Dolan, Capgemini Consulting – New York Rohit Mahajan, Capgemini Consulting – New York The information contained in this document is proprietary. ©2015 Capgemini. All rights reserved. Rightshore® is a trademark belonging to Capgemini. About Capgemini Consulting Capgemini Consulting is the global strategy and transformation consulting organization of the Capgemini Group, specializing in advising and supporting enterprises in significant transformation, from innovative strategy to execution and with an unstinting focus on results. With the new digital economy creating significant disruptions and opportunities, our global team of over 3,600 talented individuals work with leading companies and governments to master Digital Transformation, drawing on our understanding of the digital economy and our leadership in business transformation and organizational change. For more information: www.capgemini-consulting.com About Capgemini With 180,000 people in over 40 countries, Capgemini is one of the world’s foremost providers of consulting, technology and outsourcing services. The Group reported 2014 global revenues of EUR 10.573 billion (about $14 billion USD at 2014 average rate). Together with its clients, Capgemini creates and delivers business, technology and digital solutions that fit their needs, enabling them to achieve innovation and competitiveness. A deeply multicultural organization, Capgemini has developed its own way of working, the Collaborative Business ExperienceTM, and draws on Rightshore® , its worldwide delivery model. Learn more about us at www.capgemini.com Rightshore® is a trademark belonging to Capgemini